Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06324968

Ro60 Expression in Macrophages in Sjogren's Disease

Ro60 Expression in Macrophages in Patients with Primary Sjogren's Syndrome

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

Context: The Ro60 protein associates with YRNAs (or RNYs) to form the RoRNP complex, which regulates RNA surveillance and maturation. It is hypothesized that its impairment by nuclear penetration of the anti-Ro60 autoantibodies, would deregulate the anti-inflammatory response in monocytes/macrophages (Mo/Mp) in patients with Sjögren's disease (SD).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPositive serology for anti-SSABlood sample which detect serology for anti-SSA.

Timeline

Start date
2024-02-09
Primary completion
2024-12-13
Completion
2025-05-09
First posted
2024-03-22
Last updated
2025-03-11

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06324968. Inclusion in this directory is not an endorsement.

Ro60 Expression in Macrophages in Sjogren's Disease (NCT06324968) · Clinical Trials Directory